Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Mar 5, 2026, 15:35Ney Carter Borges: Cholesterol-Inflammation Fusion in Atherosclerosis
-
Mar 5, 2026, 15:33Nicolas Hubacz: How Stress Shapes Organ Development
-
Mar 5, 2026, 15:28Charles Greenberg: What If D-dimer Isn’t ‘Non-Specific’ At All?
-
Mar 5, 2026, 15:27Reza Bavarsad Shahripour: When Waveform Patterns Tell the Story of Proximal Flow
-
Mar 5, 2026, 15:23Mud Alvi: The Interaction Between LV Injury and Cryptogenic Stroke
-
Mar 5, 2026, 15:23Crina Chrysostomou: Residents vs AI in the Detection of Intracranial Hemorrhage on Emergency CT
-
Mar 5, 2026, 15:22Registration and Abstract Submission for ESH BMFS 2026 Are Now Open – ESH
-
Mar 5, 2026, 15:17Lucie Raskin: New FAERS Evidence Suggests Lower VTE Risk With Natural Estrogen COCs
-
Mar 5, 2026, 15:08Gijs Aertssen: Predictors of Recovery After Joint Bleeds in Patients with Bleeding Disorders